<DOC>
	<DOCNO>NCT02653027</DOCNO>
	<brief_summary>The purpose research study find combined therapy lumacaftor-ivacaftor effect people cystic fibrosis respond oral glucose tolerance test , test diabetes .</brief_summary>
	<brief_title>Effect Lumacaftor-ivacaftor Glucose Handling Tolerance Cystic Fibrosis Phe508del</brief_title>
	<detailed_description>This single center , open label study crossover patient Cystic Fibrosis ( CF ) . Patients 2-3 visit Diabetes Center Massachusetts General Hospital ( MGH ) . The participant previously screen clinically make sure candidate start combination drug , lumacaftor-ivacaftor . These patient contact prior first visit discus enrollment study . At first study visit ( Visit 1 ) , participant come Diabetes Center overnight fast least 8 hour . The follow occur study visit : informed consent ; brief medical history ; weight height ; vital sign blood pressure ; blood draw DNA extraction , extra research tube storage ; administration 75g Glucola load per standard oral glucose tolerance test ( OGTT ) protocol ; blood work glucose insulin 30 , 60 , 90 120 minute glucose load . This scheduled time convenient patient , attempt coordinate patient 's visit CF clinic prior start lumacaftor-ivacaftor combination drug . At 2nd study visit ( Visit 2 ) , take place 3 month start combination drug , participant come Diabetes Center overnight fast least 8 hour . The participant undergo second OGTT first visit . The 3rd study visit ( Visit 3 ) 6 month initiation drug , repeat administration OGTT . If participant start combination drug enrol study , he/she still participate study long clinical OGTT perform within 6 month start combination drug . In case , informed consent , brief medical history , weight height vital sign blood pressure , well blood draw DNA occur Visit 2 , first study visit participant . If clinical OGTT perform prior within 6 month start combination therapy , OGTT use analysis data , although full amount data study OGTT .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Age 18 year old great 2 . Patients diagnose CF , genotype homozygous PheDel508 3 . Subject plan start lumacaftorivacaftor clinical reason , contraindication start drug* OR subject take combination drug OGTT do partner facility 6 month prior initiate drug . Contraindications take drug include abnormal liver enzyme test , renal dysfunction , pregnancy nursing mother 1 . Currently take medication diabetes ( include oral injectable antihyperglycemic agent and/or insulin ) . 2 . Had admission CF exacerbation le 2 week prior star medication . This define require new IV PO antibiotic different use maintenance therapy . 3 . Is currently take oral glucocorticoid oral IV glucocorticoid past 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Genetics</keyword>
</DOC>